Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Prelude Therapeutics Inc
(NQ:
PRLD
)
1.340
-0.090 (-6.29%)
Streaming Delayed Price
Updated: 3:24 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
517,958
Open
1.400
Bid (Size)
1.330 (52)
Ask (Size)
1.340 (2)
Prev. Close
1.430
Today's Range
1.325 - 1.420
52wk Range
1.390 - 6.800
Shares Outstanding
54,808,715
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
October 24, 2024
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
October 09, 2024
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST)
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Performance
YTD
-67.08%
-67.08%
1 Month
-35.27%
-35.27%
3 Month
-77.44%
-77.44%
6 Month
-64.46%
-64.46%
1 Year
-24.29%
-24.29%
More News
Read More
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
September 13, 2024
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Morgan Stanley Downgrades Prelude Therapeutics: Here's What You Need To Know
December 19, 2023
Via
Benzinga
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
September 09, 2024
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
August 14, 2024
Via
Benzinga
PRLD Stock Earnings: Prelude Therapeutics Misses EPS for Q2 2024
August 12, 2024
Via
InvestorPlace
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers
July 09, 2024
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
June 22, 2024
Via
Talk Markets
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
June 03, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference
May 09, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024
May 07, 2024
Via
InvestorPlace
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
April 09, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
March 05, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
February 29, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
February 16, 2024
Via
Benzinga
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
February 15, 2024
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Prelude Therapeutics Announces $25 Million Private Placement
December 11, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
November 01, 2023
From
Prelude Therapeutics, Inc.
Via
GlobeNewswire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
November 01, 2023
From
Prelude Therapeutics, Inc.; AbCellera
Via
GlobeNewswire
Best Buy To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Thursday
October 19, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.